With over 600 virtual sessions and events, AIDS 2020: Virtual will enable delegates to access and engage with the latest HIV science, advocacy and knowledge traditionally presented at the conference, while offering a range of new features made possible by the new virtual format.
Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic.
7 July 2020
Lives session: 9 to 10 am PST: Satellite Channel 2
Repeat: 12 to 1 PM PST – Satellite Channel 3
HIV Vaccine: the search goes on!
Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Diverse and promising HIV vaccines candidates are in various stages of development and exciting results from vaccine efficacy and passive immunization trials are expected in the coming years. The vaccine field remains hopeful and determined – even with the necessary shift in attention to developing SARS-CoV-2 control measures. Communicating the wealth and breadth of ongoing research, and the steadfast commitments of funders, researchers, product developers and communities to find a vaccine remains critically important. Co-sponsored by the Enterprise, NIH/HVTN/HPTN, with the participation of the South African Medical Research Council, IAVI, EU consortiums and AVAC, this satellite will showcase current HIV vaccine research and development.
Organizer: International AIDS Society.
Presentation: The challenges of developing a vaccine: Compare and contrast HIV & SARS-CoV-2. Jerome Kim, International Vaccine Institute (IVI).
Moderator: Mitchell Warren, AVAC; Nina Russell, Bill and Melinda Gates Foundation.
Panellists: Glenda Gray, South African Medical Research Council; Luc Debruyne, CEPI; Sanjay Gurunathan, Sanofi; Martin Friede, WHO; Robin Shattock, Imperial College London; Maureen Luba, AVAC / COMPASS.
7 July 2020
Lives session: 9 to 10 am PST – Satellite Channel 1 – Repeat: Wednesday 8 July 2-3 AM PST – Satellite Channel 1
Road to a Vaccine Live Broadcast from AIDS 2020
During this hour, award-winning journalist Lisa Ling will be interviewing community leaders, advocates and scientists to talk about why the development of an HIV vaccine remains an essential need, discuss how the learnings from the quest to develop an HIV vaccine are being applied to expedite the delivery of COVID-19 vaccines, explore why it is essential to ensure the representation of diverse individuals and communities in vaccine clinical trials, and highlight how we can empower self-care and best support the needs of those living with HIV during this unprecedented time. Audience members will be able to ask questions of this panel.
Organizer: Johnson & Johnson / Janssen Pharmaceuticals.
9 july 2020
Lives session: 5PM PST – Auditorium
Biomedical HIV prevention: Beyond daily oral prep
This talk will cover why, despite its high efficacy, daily oral PrEP alone is not sufficient to reach all populations who need highly effective prevention strategies. Strategies including scale up of treatment (U=U); alternate PrEP dosing schedules, drugs, and modes of delivery; post-exposure prophylaxis; and HIV vaccines will be discussed
Speaker: Susan Buchbinder, University of California, San Francisco.
SS05 – Trials, tribulations and prevention
Symposia and bridging sessions On-Demand Channel
Moderators: Prof. Kenneth Mayer, Fenway Health, Helen Rees, Wits RHI, ECHO Committee Consortium.
This session will assess the complexities of HIV prevention trial design in the era of effective PrEP and discuss alternative designs and analytic techniques to help guide the design of future prevention trials. Given the proven efficacy of oral PrEP, the design of studies to determine the efficacy of new prevention technologies has become more complex. This session will be a state-of-the-art update of ongoing HIV prevention trials and new options coming soon into trials. It will explore theoretical and practical issues influencing trial design in an era when effective HIV prevention using oral PrEP is already widely available. This will include the use of different endpoints, new statistical analysis techniques, ethical considerations and practical issues of enrolling and randomizing patients in HIV prevention trials.
OAA03 – HIV vaccine development: How to forge ahead
Abstract Sessions On-Demand Channel
Moderators: Sandhya Vasan, MHRP
- OAA0302 – Multivariant HIV-1 infection in infants with broadly neutralizing plasma antibodies: Implication for polyvalent vaccines.
Nitesh Mishra, All India Institute of Medical Sciences.
- OAA0304 – Priming with DNA expressing trimeric V1V2A244 alters the immune hierarchy and favors the development of V2-specific HIV antibodies in rhesus macaques.
George N. Pavlakis, National Cancer Institute at Frederick.
- OAA0305 – Sequence and structure guided HIV-1 clade C trimeric immunogen design to induce neutralizing and V1V2 directed antibody responses.
Anusmita Sahoo, Emory University.
- OAA0306 – Protective efficacy of a vaccine inducing Gag/Vif-specific CD8+ T but not CD4+ T cells against repeated intrarectal low-dose SIVmac239 challenges.
Hiroshi Ishii, National Institute of Infectious Diseases.
- OAA0307 – Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge.
Barbara K. Felber, National Cancer Institute at Frederick.
OAALB01 – Track A late-breaker abstracts
Prime Channel-Live sessions
- OAALB010 – Induction of cross-neutralizing antibodies and protection from heterologous tier-2 SHIV challenge by an mRNA-based vaccine in macaques.
Paolo Lusso, NIH.
- OAALB0102 – HIV envelope BG505 SOSIP immunization induces autologous virus and CD4 binding site-specific B cell lineage antibody precursor responses in infant rhesus macaques.
Ashley N. Nelson, Duke University Medical Center.
- OAALB0103 – CCR5 antibody blockade protects rhesus macaques from rectal SHIV acquisition.
Xiao Chang, Oregon Health and Science University.
- OAALB0104 – Vaccination against HIV-1 with interbilayer cross-linked multilamellar vesicles carrying SOSIP trimer.
Charles Park, University of Michigan.
The Global HIV Vaccine Enterprise (the Enterprise) unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of—and future access to—an HIV vaccine.
Global HIV Vaccine Enterprise
International AIDS Society
Avenue de France 23